SL
CRSP icon

Stevard LLC’s CRISPR Therapeutics CRSP Stock Holding History

Stevard LLC’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-5,011
Closed -$271K – 29
2024
Q2 		$271K Sell
5,011
-396
-7% -$22.9K 0.23% 50
2024
Q1 		$369K Buy
5,407
+121
+2% +$8.66K 0.33% 39
2023
Q4 		$331K Buy
+5,286
New +$292K 0.33% 40
2023
Q3 		– Sell
-4,356
Closed -$245K – 45
2023
Q2 		$245K Sell
4,356
-1,362
-24% -$77.3K 0.23% 42
2023
Q1 		$259K Hold
5,718
– – 0.24% 44
2022
Q4 		$232K Hold
5,718
– – 0.2% 44
2022
Q3 		$374K Buy
+5,718
New +$414K 0.35% 38
2022
Q1 		$359K Sell
5,718
-969
-14% -$60.8K 0.28% 42
2021
Q4 		$507K Sell
6,687
-1,350
-17% -$118K 0.36% 36
2021
Q3 		$900K Buy
8,037
+94
+1% +$11.8K 0.71% 23
2021
Q2 		$1.29M Buy
7,943
+42
+0.5% +$5.11K 0.99% 22
2021
Q1 		$963K Sell
7,901
-604
-7% -$91.2K 0.79% 22
2020
Q4 		$1.3M Sell
8,505
-3,243
-28% -$383K 0.44% 30
2020
Q3 		$983K Buy
11,748
+2,320
+25% +$206K 0.41% 38
2020
Q2 		$693K Buy
+9,428
New +$551K 0.35% 41

Other funds holding CRSP

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Stevard LLC's CRSP Position: Q3 2024 in Review

Stevard LLC sold out of CRISPR Therapeutics (CRSP) in Q3 2024, closing a stake of 5,011 shares — an estimated $271K sold.

Stevard LLC first reported a position in CRSP in Q2 2020 and held it in 15 quarters. The position peaked at $1.3M in Q4 2020. 416 funds tracked by Wall St. Rank hold CRSP as of Q3 2024.

  • Stevard LLC reported no remaining CRISPR Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Stevard LLC sold 5,011 CRISPR Therapeutics shares in Q3 2024, an estimated $271K.
  • Stevard LLC first reported a position in CRISPR Therapeutics in Q2 2020 and held it in 15 quarters.
  • Stevard LLC's CRISPR Therapeutics position peaked at $1.3M in Q4 2020.
  • 416 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2024.

Based on Stevard LLC's 13F filing for Q3 2024, filed 14 Nov 2024.